A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis

Clinical trial NCT02282826 · COMPLETED

Trial details

NCT number: NCT02282826
Sponsor: Genzyme, a Sanofi Company
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Progressive Multiple Sclerosis

Start date: 2014-10-01
Primary completion: 2016-03-01
Enrollment: 48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.